Kasim Kutay
CEO @ Novo Holdings
London, United Kingdom
Kasim Kutay is a Series A investor at Novo Holdings in London focused on Biotechnology and Health Care. Kasim Kutay
- Total investments:
- 2
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Kasim Kutay invests in
Stages Kasim Kutay invests in
Countries Kasim Kutay invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 2 (100%)
- Health Care 1 (50%)
- Therapeutics 1 (50%)
Stage
- Series A 1 (50%)
- Series C 1 (50%)
Country
- Singapore 1 (50%)
- Switzerland 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression. | $100M / Series C / Jul 16, 2024 | ||
| Esco Lifesciences Group provides enabling technologies, products, and services for the life sciences and healthcare industries, supporting academic research and scientific discoveries, clinical practice, as well as biopharmaceutical R&D and manufacturing. | $200M / Series A / May 26, 2021 |
Co-Investors
About Novo Holdings
Novo Holdings is a holding and investment firm that manages the assets of the Novo Nordisk Foundation. It is a life science investor with a diverse portfolio that includes equities, bonds, real estate, infrastructure, and private investments.
Novo Holdings Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Emmanuelle Coutanceau
Partner Novo Seeds
|
|||
Steve Collins
National Account Executive
|
|||
Thomas Dyrberg
Partner
|
|||
Thomas Grotkjær
Investor & Principal
|
|||
Abhijeet Lele
Senior Partner and Head of US Principal Investments
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Kasim Kutay invest in?
Kasim Kutay invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series C stage. Most of the 2 investments tracked by Shizune back companies in Singapore. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Kasim Kutay?
Public channels for Kasim Kutay include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Kasim Kutay last invest?
The most recent investment recorded for Kasim Kutay closed in Jul 2024. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
